Large clinical trials, called the EVOKE studies, are happening right now all around the world to find out if these drugs can actually slow down memory loss in people with Alzheimers
HbA1c values attained a plateau in the 2 groups of patients receiving CagriSema and semaglutide at 20 weeks, whereas in the cagrinlitide group the decrease in HbA1c was more gradual and was progressive up to the end of treatment at 32 weeks [10]
Until such data exists, conclusions about their relative cognitive enhancement potential in humans remain speculative
Always help patients understand their options clearly, so they can make informed decisions about their care and cost
Personalized Approach These treatments are tailored to individual needs, ensuring better outcomes
doi: 10.3389/fcell.2021.737314 67 JamilNNawroozMBishoyiABallalSSinghAKrithigaT